Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03672292 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
A Phase 2 study, sponsored by Scynexis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03672292 is a Phase 2 study that was terminated before completion, run by Scynexis. The registered enrollment target is 22 participants.
The verdict
NCT03672292, a Phase 2 study, was terminated before completion, sponsored by Scynexis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
Interventions
- DRUG Voriconazole
- DRUG SCY-078
- OTHER Oral Placebo Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-01-22 |
| Est. Completion | 2023-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03672292
The ClinicalTrials.gov registry entry for NCT03672292 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Voriconazole is the first listed.
NCT03672292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03672292 about?
NCT03672292 is a clinical study titled "Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis". Study to evaluate the safety and efficacy of coadminstration of SCY-078 with a mold-active azole (voriconazole) compared to voriconazole in patients with invasive pulmonary aspergillosis.
What is the current status of trial NCT03672292?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-01-22. Estimated completion is 2023-03-27.
What interventions are being tested in trial NCT03672292?
The interventions under investigation include: Voriconazole (DRUG), SCY-078 (DRUG), Oral Placebo Tablets (OTHER).
Who is sponsoring clinical trial NCT03672292?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.